Physician profile
Ellen Barton Blackmon
NPI 1972723179
$1,135.00
in general payments reported to CMS, 2019-2025
18 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.56 · 2021: $130 · 2022: $220 · 2023: $214 · 2024: $308 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.13 | 2020-2024 | Venclexta |
| Hologic Sales and Service, LLC | $215.33 | 2024-2025 | 3dimensions |
| Incyte Corporation | $113.70 | 2021-2024 | Monjuvi, Pemazyre |
| Csl Behring | $102.53 | 2024-2025 | Hizentra |
| Genentech USA, INC. | $77.54 | 2023-2025 | Tecentriq |
| Pharmaessentia USA Corporation | $56.05 | 2023-2024 | Besremi |
| Hema Biologics, LLC | $54.36 | 2023 | Sevenfact |
| Novartis Pharmaceuticals Corporation | $43.20 | 2023-2025 | |
| Amgen INC. | $39.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.13 | 2022 | |
| Merck Sharp & Dohme LLC | $28.05 | 2025 | Keytruda, Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.66 | 2021 | |
| Dova Pharmaceuticals | $20.83 | 2021 | |
| Beigene USA, INC. | $16.71 | 2023 | Brukinsa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.86 | 2024 | Orgovyx |
| Grifols USA, LLC | $14.58 | 2020 | |
| Seagen INC. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.